Immuneering Corp
IMRX· Nasdaq
IMRXImmuneering Corp
Filed Aug 10, 2022 · 10-Q · 41 days after period end · 0001558370-22-013063
| Metric | Q2 2022 | Q2 2021 | Q2 2020 |
|---|---|---|---|
| Revenue | $94.42K | $660.04K | $480.84K |
| Net Income | -$11.53M | -$7.99M | -$3.60M |
| EPS Diluted | -$0.44 | -$1.61 | -$0.73 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Immuneering Corp · CIK 1790340 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 10, 2022 · 41 d after period end
